Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Oncoimmunology|March 26, 2013
Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patientsTrine Zeeberg Iversen, Marie Klinge Brimnes, Kirsten Nikolajsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patientsPaolo Bruzzi, Lucia Del Mastro, Maria P Sormani, et al.
Melanoma Research|April 15, 2016
Prognostic and predictive value of YKL-40 in stage IIB-III melanomaMerete Krogh, Ib Christensen, Marna Bouwhuis, et al.
Cancer Epidemiology|November 28, 2012
Papillary thyroid carcinoma in Denmark 1996-2008: an investigation of changes in incidenceStefano Christian Londero, Annelise Krogdahl, Lars Bastholt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanomaMicaela Hernberg, Petri S Mattila, Marjo Rissanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaJohn M Kirkwood, Lars Bastholt, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA TrialMichael C Kreissl, Lars Bastholt, Rossella Elisei, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2019
The real-world impact of modern treatments on the survival of patients with metastatic melanomaMarco Donia, Eva Ellebaek, Trine Heide Øllegaard, et al.
Cancer Epidemiology|May 7, 2021
The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patientsEva Ellebaek, Inge Marie Svane, Henrik Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2025
Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanomaRasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Oncoimmunology|March 26, 2013
Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patientsTrine Zeeberg Iversen, Marie Klinge Brimnes, Kirsten Nikolajsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patientsPaolo Bruzzi, Lucia Del Mastro, Maria P Sormani, et al.
Melanoma Research|April 15, 2016
Prognostic and predictive value of YKL-40 in stage IIB-III melanomaMerete Krogh, Ib Christensen, Marna Bouwhuis, et al.
Cancer Epidemiology|November 28, 2012
Papillary thyroid carcinoma in Denmark 1996-2008: an investigation of changes in incidenceStefano Christian Londero, Annelise Krogdahl, Lars Bastholt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanomaMicaela Hernberg, Petri S Mattila, Marjo Rissanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaJohn M Kirkwood, Lars Bastholt, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA TrialMichael C Kreissl, Lars Bastholt, Rossella Elisei, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2019
The real-world impact of modern treatments on the survival of patients with metastatic melanomaMarco Donia, Eva Ellebaek, Trine Heide Øllegaard, et al.
Cancer Epidemiology|May 7, 2021
The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patientsEva Ellebaek, Inge Marie Svane, Henrik Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2025
Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanomaRasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, et al.
Pageof 14